Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets

Journal of Virology

Volumn 85, Issue 6, 2011, Pages 2695-2702

  Bodewes, R ^a   Kreijtz, J H C M ^a   Geelhoed Mieras, M M ^a   Van Amerongen, G ^a,b   Verburgh, R J ^a   Van Trierum, S E ^a   Kuiken, T ^a   Fouchier, R A M ^a   Osterhaus, A D M E ^a,b   Rimmelzwaan, G F ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ViroClinics Biosciences BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CROSS REACTION; FEMALE; HISTOPATHOLOGY; IMMUNITY; INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VIRUS A H3N2; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYMPTOMATOLOGY; T LYMPHOCYTE; UPPER RESPIRATORY TRACT; VACCINATION; VIRUS REPLICATION;

ANIMALS; BRAIN; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FEMALE; FERRETS; HISTOCYTOCHEMISTRY; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY SYSTEM; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

AVIAN INFLUENZA VIRUS; MUSTELA; ORTHOMYXOVIRIDAE;

EID: 79952404440     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02371-10     Document Type: Article

References (48)

1. Benton, K. A., et al. 2001. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J. Immunol. 166:7437-7445. (Pubitemid 32525621)
2. Bernstein, D. I., et al. 2008. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197:667-675.
3. Bodewes, R., et al. 2009. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One 4:e5538.
4. Bodewes, R., et al. 2010. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J. Gen. Virol. 91:1743-1753.
5. Bodewes, R., J. H. Kreijtz, and G. F. Rimmelzwaan. 2009. Yearly influenza vaccinations: a double-edged sword? Lancet Infect. Dis. 9:784-788.
6. Bodewes, R., et al. 2010. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J. Virol. 84:7943-7952.
7. Bodewes, R., G. F. Rimmelzwaan, and A. D. Osterhaus. 2010. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev. Vaccines 9:59-72.
8. Butler, D. 2010. Portrait of a year-old pandemic. Nature 464:1112-1113.
9. de Wit, E., et al. 2005. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J. Virol. 79:12401-12407.
10. Ellebedy, A. H., et al. 15 September 2010. Impact of prior seasonal influenza vaccination and infection on pandemic A(H1N1) influenza virus replication in ferrets. Vaccine [Epub ahead of print.] doi:10.1016/j.vaccine. 2010.08.067.
11. Epstein, S. L. 2006. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J. Infect. Dis. 193:49-53.
12. Girard, M. P., J. Katz, Y. Pervikov, L. Palkonyay, and M. P. Kieny. 2010. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials, World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine 28:6811-6820.
13. Girard, M. P., A. Osterhaus, Y. Pervikov, L. Palkonyay, and M. P. Kieny. 2008. Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses," World Health Organization, Geneva, Switzerland, 3-4 December 2007. Vaccine 26:2443-2450.
14. Govorkova, E. A., et al. 2005. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J. Virol. 79:2191-2198. (Pubitemid 40204576)
15. Grebe, K. M., J. W. Yewdell, and J. R. Bennink. 2008. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10:1024-1029.
16. Heinen, P. P., E. A. de Boer-Luijtze, and A. T. Bianchi. 2001. Respiratory and systemic humoral and cellular immune responses of pigs to a heterosubtypic influenza A virus infection. J. Gen. Virol. 82:2697-2707.
17. Janjua, N. Z., et al. 2010. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada. Clin. Infect. Dis. 51:1017-1027.
18. Karber, G. 1931. Beitrag zur kollektiven behandlung pharmakologischer reihenversuche. Exp. Pathol. Pharmakol. 162:480-483.
19. Keitel, W. A., et al. 2008. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J. Infect. Dis. 198:1309-1316.
20. Kelly, H., and I. Barr. 2010. Large trials confirm immunogenicity of H1N1 vaccines. Lancet 375:6-9.
21. Kreijtz, J. H., et al. 2009. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27:4983-4989.
22. Laurie, K. L., et al. 2010. Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J. Infect. Dis. 202:1011-1020.
23. Lemaitre, M., and F. Carrat. 2010. Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infect. Dis. 10:162.
24. Leroux-Roels, I., et al. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589. (Pubitemid 47247854)
25. Liang, S., K. Mozdzanowska, G. Palladino, and W. Gerhard. 1994. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1653-1661.
26. Nguyen, H. H., F. W. van Ginkel, H. L. Vu, J. R. McGhee, and J. Mestecky. 2001. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J. Infect. Dis. 183:368-376.
27. Nicholson, K. G., et al. 2001. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943. (Pubitemid 32568336)
28. O'Neill, E., S. L. Krauss, J. M. Riberdy, R. G. Webster, and D. L. Woodland. 2000. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J. Gen. Virol. 81:2689-2696.
29. Palmer, D., W. Dowle, M. Coleman, and G. Schild. 1975. Haemagglutination inhibition test, p. 25-62. In Advances in laboratory techniques for influenza diagnosis: procedural guide. U.S. Department of Health, Education and Welfare, Atlanta, GA.
30. Park, C. H., et al. 2002. The invasion routes of neurovirulent A/Hong Kong/483/97 (H5N1) influenza virus into the central nervous system after respiratory infection in mice. Arch. Virol. 147:1425-1436.
31. Price, G. E., et al. 2010. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 5:e13162.
32. Rimmelzwaan, G. F., M. Baars, E. C. Claas, and A. D. Osterhaus. 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J. Virol. Methods 74:57-66.
33. Rimmelzwaan, G. F., et al. 1999. Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Vaccine 17:2512-2516. (Pubitemid 29314443)
34. Rimmelzwaan, G. F., R. A. Fouchier, and A. D. Osterhaus. 2007. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18:529-536.
35. Rimmelzwaan, G. F., et al. 2001. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J. Virol. 75:6687-6691. (Pubitemid 32578188)
36. Rimmelzwaan, G. F., et al. 1990. Establishment and characterization of canine parvovirus-specific murine CD4+ T cell clones and their use for the delineation of T cell epitopes. J. Gen. Virol. 71:1095-1102.
37. Sandbulte, M. R., et al. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4:e59.
38. Schotsaert, M., M. De Filette, W. Fiers, and X. Saelens. 2009. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines 8:499-508.
39. Seo, S. H., and R. G. Webster. 2001. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J. Virol. 75:2516-2525.
40. Skowronski, D. M., et al. 2010. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Med. 7:e1000258.
41. Smallman-Raynor, M., and A. D. Cliff. 2007. Avian influenza A (H5N1) age distribution in humans. Emerg. Infect. Dis. 13:510-512.
42. Stohr, K. 2010. Vaccinate before the next pandemic? Nature 465:161.
43. van den Brand, J. M., et al. 2010. Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J. Infect. Dis. 201:993-999.
44. Vesikari, T., N. Groth, A. Karvonen, A. Borkowski, and M. Pellegrini. 2009. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27:6291-6295.
45. Waddington, C. S., et al. 2010. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340:c2649.
46. Wang, T. T., et al. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U. S. A. 107:18979-18984.
47. World Health Organization (WHO). 9 December 2010, posting date. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. WHO, Geneva, Switzerland. http://www.who.int/csr/disease/avian- influenza/country/cases-table-2010-12-09/en/index.html.
48. Zitzow, L. A., et al. 2002. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virol. 76:4420-4429. (Pubitemid 34309579)